Anika Therapeutics, Inc.
$197.18M- Market cap
- $278.50M
- Debt
- +-$149.00K
- Cash
- −$81.17M
Capital structure 100% equity / -0% debt · EV / Revenue 1.75x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: ANIK stock price at premium vs PSX $20.81 current versus $6.48 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PSX's multiple
Implied fair value · at ANIK's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ANIK FY 2025 (ended Dec 31, 2025) · PSX FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 100% equity / -0% debt · EV / Revenue 1.75x
Capital structure 84% equity / 16% debt · EV / Revenue 0.91x · EV / EBITDA 18.80x
PSX carries the larger enterprise value at $120.39B against $197.18M; PSX trades on the lower EV / Revenue multiple (0.91x vs 1.75x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Anika Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Phillips 66 · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-0.00x
0.68x
Net debt / EBITDA
Leverage against operating earnings
34.65x
2.90x
Cash and equivalents
Liquid reserves on the balance sheet
$81.17M
$1.12B
Total debt
Interest-bearing obligations outstanding
-$149.00K
$19.72B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ZIMMER BIOMET HOLDINGS, INC.
ANIK vs ZBH
STRYKER CORP
ANIK vs SYK
BECTON DICKINSON & CO
ANIK vs BDX
INTEGRA LIFESCIENCES HOLDINGS CORP
ANIK vs IART
VALERO ENERGY CORP/TX
ANIK vs VLO
Marathon Petroleum Corp
ANIK vs MPC
CONOCOPHILLIPS
ANIK vs COP
EXXON MOBIL CORP
ANIK vs XOM
CHEVRON CORP
ANIK vs CVX
HALLIBURTON CO
ANIK vs HAL
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.